In that spirit, proposals are now being accepted for Biomedical Innovation Funding Awards (BIFAs) — with initial areas of focus in biologics and nanotechnology.
Examples of welcome proposals are those focused on the development and/or optimization of technologies that enable faster, cost-effective methods for developing and manufacturing antibodies and proteins. These might include new technologies for efficient production, host selection, new bioreactor designs, new recovery techniques, and novel formulation/stabilization strategies.
Nanotechnology proposals for delivering small molecules, biologics, or siRNAs specifically for treating cancer, diabetes, inflammation, aging, fibrosis and the eye (i.e. painless delivery methods) are welcome, as are proposals for innovative nanotechnology-based sensing modalities. Highly innovative applications in other areas will be considered.
The funds available will provide MIT researchers with financial support to enable innovative research projects in furtherance of the objectives of a strategic alliance that sanofi-aventis and MIT entered into on May 5. It is anticipated that awards will be between $100,000-$150,000 per year with periods of performance of up to three years. It is estimated that between five and eight awards will be made this year. The next request for proposals will be issued within the first year of the program.
- July 14, 2010: BIFA application deadline
- July 28, 2010: Review/selection of proposals by MIT/sanofi-aventis Joint Scientific Steering Committee
- Sept. 1, 2010: Earliest start date for BIFA projects